Innoviva's (INVA) Buy Rating Reaffirmed at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I restated their buy rating on shares of Innoviva (NASDAQ:INVA – Get Rating) in a research note released on Thursday, Benzinga reports. The firm currently has a $22.50 price target on the biotechnology company’s stock. A number of other analysts have also recently issued reports on the company. StockNews.com assumed coverage […]

Related Keywords

Relvar Breo Ellipta ,Anoro Ellipta ,Pavel Raifeld ,Summerhaven Investment Management ,Innoviva Company Profile ,Mirae Asset Global Investments Co ,Innoviva Inc ,Advisor Group Holdings Inc ,Goldman Sachs Group ,Ef Hutton Acquisition Co ,Securities Exchange Commission ,Morgan Stanley ,Money Concepts Capital Corp ,Get Rating ,Exchange Commission ,Haven Investment Management ,Concepts Capital Corp ,Group Holdings ,Mirae Asset Global Investments ,Asset Global Investments ,Innoviva Daily ,Innoviva ,Nasdaq Inva ,Minva ,Medical ,88338t10 ,Reiterated Rating ,Ef Hutton Acquisition Co I ,